Bluebird is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. With its lentiviral-based gene therapy
and gene editing capabilities, the Company has built an integrated product platform with broad potential application in these areas. bluebird’s clinical programs in severe genetic diseases include its
LentiGlobin product candidate to treat transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease (SCD), and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy
(CALD). In oncology, bluebird is developing bb2121 and bb21217, which are anti-BCMA CAR T product candidates for the treatment of multiple myeloma that are exclusively licensed to Celgene.